Actavis is pleased to inform you about the launch of Aritavi 30mg and 60mg hard gastro-resistant capsules.

Aritavi contains duloxetine. Duloxetine is classified as an SNRI anti-depressant.

 

Indication

Starting Dose

Maintenance dose

Maximum dose

Duration of treatment

Major depressive Disorder

60mg od

60mg od

120mg od

Treatment to be continued for several months, in order to avoid relapse

Generalised Anxiety Disorder (GAD)

30mg od

(60 mg – if GAD presents with comorbid major depressive episodes)

60mg od

90-120mg od

Diabetic peripheral neuropathic pain

60mg od

60mg od

120mg in evenly divided doses

Treatment reassessed every three months

 

–          Duloxetine can be taken with/without food.

Mechanism of action

Duloxetine is a combined serotonin (5‑HT) and noradrenaline (NA) reuptake inhibitor. It weakly inhibits dopamine reuptake with no significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors.

 

Aritavi 30mg Consumer price is EUR 15.83

Aritavi 60mg Consumer price is EUR 21.53

 

Please refer to our website www.actavis.com.mt for the full summary of product characteristics